Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in supportive care products for kidney disease and cancer. Flagship drugs include the red blood cell stimulators Epogen and Aranesp, the immune system stimulants Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases.
Amgen is one of the best positioned in the pharmaceutical industry. In 2020, the company generated higher earnings than in 2019, due to its strong product pipeline. Financially speaking, the company maintains controlled debt levels that it will be able to meet without any problems.
Fundamentals:
- Value
- 8.8% estimated net earnings growth over the next 3 years.
- P/E 19x vs. 29.6x industry P/E
Technicals:
- Price level cross MA 200 - 50
- Williams R% at -91% levels
- RSI (41) Neutral
- -2.8% average upside during the month
On January 28th there was a market correction, which also affected Amgen. Although the correction lasted a couple of days, the share price continued to fall until $232.10. From this point, the stock recovered 2.5% and remains at these levels; however, the recovery channel should continue as there are no clear retracement fundamentals. In terms of technical factors, we can see that the SMA and Williams R% favor a buy decision.
Amgen is one of the best positioned in the pharmaceutical industry. In 2020, the company generated higher earnings than in 2019, due to its strong product pipeline. Financially speaking, the company maintains controlled debt levels that it will be able to meet without any problems.
Fundamentals:
- Value
- 8.8% estimated net earnings growth over the next 3 years.
- P/E 19x vs. 29.6x industry P/E
Technicals:
- Price level cross MA 200 - 50
- Williams R% at -91% levels
- RSI (41) Neutral
- -2.8% average upside during the month
On January 28th there was a market correction, which also affected Amgen. Although the correction lasted a couple of days, the share price continued to fall until $232.10. From this point, the stock recovered 2.5% and remains at these levels; however, the recovery channel should continue as there are no clear retracement fundamentals. In terms of technical factors, we can see that the SMA and Williams R% favor a buy decision.
Trade closed: stop reached
25 Feb
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.